Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
AssigneeInternational Institute of Cancer Immunology, Inc.
InventorHaruo Sugiyama
Life of this patent
Estimating the term…
Abstract
Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid sequence is selected from the group consisting of Ala, Ile, Leu, Val, Phe, Tyr, Ser and Asp and an amino acid residue at position 9 in the amino acid sequence is Arg; a polynucleotide encoding the peptide; a pharmaceutical composition comprising the peptide; and a method of treating cancer using the peptide.
Claims12
A method for the treatment of cancer in a human leukocyte antigen (HLA)-A*3303 positive subject, comprising administering to the subject an isolated peptide comprising Thr Ser Glu Lys Pro Phe Ser Cys Arg (SEQ ID NO:
- 5),
- wherein the peptide binds to an HLA-A*3303 molecule and induces a Wilms' tumor 1 (WT1)-specific cytotoxic T lymphocyte (CTLs) in the subject,
- wherein the cancer is selected from leukemia, myelodysplastic syndrome, multiple myeloma, malignant lymphoma, gastric cancer, colon cancer, lung cancer, breast cancer, germ cell cancer, hepatic cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical cancer, and ovarian cancer, and
- wherein the peptide is administered via a route selected from the group consisting of intradermal, subcutaneous, intramuscular, intravenous, nasal and oral.
A method for the treatment of cancer in HLA-A*3303 positive subject, comprising administering to the subject an isolated peptide comprising Thr Ser Glu Lys Pro Phe Ser Cys Arg (SEQ ID NO:
- 5),
- wherein the peptide binds to an HLA-A*3303 molecule and induces WT1-specific CTLs in the subject,
- wherein the cancer is selected from leukemia, myelodysplastic syndrome, multiple myeloma, malignant lymphoma, gastric cancer, colon cancer, lung cancer, breast cancer, germ cell cancer, hepatic cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical cancer, and ovarian cancer, and
- wherein the composition is administered via a route selected from the group consisting of intradermal, subcutaneous, intramuscular, intravenous, nasal and oral.
Dependencies are inferred from the claim text.